CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies

Author:

Qin Hong1ORCID,Dong Zhenyuan1ORCID,Wang Xiuli2,Cheng Wesley A.1,Wen Feng13ORCID,Xue Weili14ORCID,Sun Han1,Walter Miriam2ORCID,Wei Guowei1,Smith D. Lynne1,Sun Xiuhua5,Fei Fan6ORCID,Xie Jianming6ORCID,Panagopoulou Theano I.7ORCID,Chen Chun-Wei7ORCID,Song Joo Y.8,Aldoss Ibrahim9,Kayembe Clarisse10,Sarno Luisa10,Müschen Markus7,Inghirami Giorgio G.10,Forman Stephen J.2,Kwak Larry W.1ORCID

Affiliation:

1. Toni Stephenson Lymphoma Center, Department of Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.

2. Center for CAR T Cell Therapy, Department of Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.

3. Department of Medical Oncology Cancer Center, West China Hospital, Sichuan University, Sichuan 910041, China.

4. The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450001, China.

5. The Second Affiliated Hospital of Dalian Medical University, Dalian 116044, China.

6. Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, CA 90007, USA.

7. Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.

8. Department of Pathology, City of Hope National Medical Center, Duarte, CA 91010, USA.

9. Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.

10. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA.

Abstract

BAFF receptor is a target for CAR T cell therapy of B cell malignancies, circumventing issues with CD19 antigen loss in tumors.

Funder

National Cancer Institute

Leukemia and Lymphoma Society

Beckman Research Institute, City of Hope

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3